These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 3274314)

  • 1. Comparative pharmacokinetics of cyclosporine and NVa2-cyclosporine in dogs.
    Venkataramanan R; Todo S; Zaghloul I; Lynch S; Kam I; Ptachcinski RJ; Burckart GJ; Starzl TE
    Transplant Proc; 1987 Feb; 19(1 Pt 2):1265-6. PubMed ID: 3274314
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of cyclosporine A and G pharmacokinetics.
    D'Souza MJ; Gourdikian KB; Mujukian AL
    Drug Metab Dispos; 1988; 16(6):895-7. PubMed ID: 2907472
    [No Abstract]   [Full Text] [Related]  

  • 3. Canine liver transplantation under Nva2-cyclosporine versus cyclosporine.
    Todo S; Porter KA; Kam I; Lynch S; Venkataramanan R; DeWolf A; Starzl TE
    Transplantation; 1986 Mar; 41(3):296-300. PubMed ID: 3513388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of a platelet-activating factor antagonist on circulating levels of cyclosporine in the dog.
    Tse FL; Smith HT
    Drug Metab Dispos; 1988; 16(3):497-8. PubMed ID: 2900746
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunosuppressive activity and toxicity of cyclosporine metabolites characterized by mass spectroscopy and nuclear magnetic resonance.
    Copeland KR; Yatscoff RW
    Transplant Proc; 1990 Jun; 22(3):1146-9. PubMed ID: 2349676
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacokinetics of the cyclosporine-ketoconazole interaction in dogs.
    D'mello A; Venkataramanan R; Satake M; Todo S; Takaya S; Ptachcinski RJ; Burckart GJ; Starzl TE
    Res Commun Chem Pathol Pharmacol; 1989 Jun; 64(3):441-54. PubMed ID: 2781141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologic significance of cyclosporine metabolites.
    Ryffel B; Foxwell BM; Mihatsch MJ; Donatsch P; Maurer G
    Transplant Proc; 1988 Apr; 20(2 Suppl 2):575-84. PubMed ID: 3363656
    [No Abstract]   [Full Text] [Related]  

  • 8. Nephrotoxicity of cyclosporine G and A in the Sprague-Dawley rat.
    Duncan JI; Simpson JG; Thomson AW; Whiting PH
    Transplant Proc; 1987 Feb; 19(1 Pt 2):1391-2. PubMed ID: 3274338
    [No Abstract]   [Full Text] [Related]  

  • 9. The isolation, structural characterization, and immunosuppressive activity of cyclosporin G (NVa2-cyclosporine) metabolites.
    Copeland KR; Yatscoff RW
    Ther Drug Monit; 1991 Jul; 13(4):281-8. PubMed ID: 1780958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of cyclosporin A and G with and without azathioprine regarding immunosuppressive efficacy, toxicity, and pharmacokinetics in Lewis rats.
    Hagberg RC; Hoyt EG; Billingham ME; Sibley RK; Starnes VA; Baldwin JC
    J Heart Transplant; 1988; 7(5):359-69. PubMed ID: 3058906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concomitant immunosuppressive and antibiotic therapy--reduction of cyclosporine A blood levels due to treatment with imipenem/cilastatin.
    Mraz W; Sido B; Knedel M; Hammer C
    Transplant Proc; 1987 Oct; 19(5):4017-20. PubMed ID: 3478881
    [No Abstract]   [Full Text] [Related]  

  • 12. Biologic activity of cyclosporine metabolites.
    Sewing KF; Christians U; Kohlhaw K; Radeke H; Strohmeyer S; Kownatzki R; Budniak J; Schottmann R; Bleck JS; Almeida VM
    Transplant Proc; 1990 Jun; 22(3):1129-34. PubMed ID: 2349673
    [No Abstract]   [Full Text] [Related]  

  • 13. Biotransformation of cyclosporin G in comparison to cyclosporine.
    Mangold JB; Schran HF; Yatscoff RW; Weitzel WF; Leichtman AB
    Transplant Proc; 1994 Oct; 26(5):3013-6. PubMed ID: 7940950
    [No Abstract]   [Full Text] [Related]  

  • 14. [Determination of cyclosporine in whole blood by reversed phase high performance liquid chromatography].
    Liu XJ; Tao CH; Chen HX; Wang W
    Yao Xue Xue Bao; 1988 May; 23(5):397-400. PubMed ID: 3213523
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacokinetics of cyclosporine A in patients with nephrotic syndrome.
    Vernillet L; Moulin B; Dadoun C; Le Bigot JF; Fillastre JP
    Transplant Proc; 1988 Apr; 20(2 Suppl 2):529-35. PubMed ID: 3363653
    [No Abstract]   [Full Text] [Related]  

  • 16. Cyclosporine pharmacokinetics in rats and interspecies comparison in dogs, rabbits, rats, and humans.
    Sangalli L; Bortolotti A; Jiritano L; Bonati M
    Drug Metab Dispos; 1988; 16(5):749-53. PubMed ID: 2906601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ocular pharmacokinetics of subconjunctivally administered cyclosporine in the rabbit.
    Kalsi GS; Gudauskas G; Bussanich N; Freeman DJ; Rootman J
    Can J Ophthalmol; 1991 Jun; 26(4):200-5. PubMed ID: 1889021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine.
    Venkataramanan R; Jain A; Warty VW; Abu-Elmagd K; Furakawa H; Imventarza O; Fung J; Todo S; Starzl TE
    Transplant Proc; 1991 Feb; 23(1 Pt 2):931-3. PubMed ID: 1703355
    [No Abstract]   [Full Text] [Related]  

  • 19. Cyclosporine pharmacokinetics and blood level monitoring.
    Burkle WS
    Drug Intell Clin Pharm; 1985 Feb; 19(2):101-5. PubMed ID: 3882375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uptake and metabolism of cyclosporin A and SDZ IMM 125 in the human in vitro skin2 dermal and barrier function models.
    Vickers AE; Biggi WA; Dannecker R; Fischer V
    Life Sci; 1995; 57(3):215-24. PubMed ID: 7596228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.